Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was the target of unusually large options trading on Friday. Traders purchased 5,053 call options on the stock. This represents an increase of approximately 548% compared to the typical daily volume of 780 call options.

In other news, Director Daniel G. Welch sold 217 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the sale, the director now owns 3,710 shares in the company, valued at $470,279.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark Pruzanski sold 1,434 shares of the firm’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $121.78, for a total value of $174,632.52. Following the sale, the chief executive officer now owns 570,284 shares in the company, valued at approximately $69,449,185.52. The disclosure for this sale can be found here. Insiders have sold 8,013 shares of company stock worth $966,747 in the last 90 days. Insiders own 4.50% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ICPT. Teachers Advisors LLC lifted its position in Intercept Pharmaceuticals by 9.5% during the 4th quarter. Teachers Advisors LLC now owns 15,410 shares of the biopharmaceutical company’s stock worth $1,674,000 after acquiring an additional 1,339 shares during the last quarter. US Bancorp DE acquired a new position in Intercept Pharmaceuticals during the 1st quarter worth $130,000. Bank of New York Mellon Corp lifted its position in Intercept Pharmaceuticals by 10.2% during the 1st quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock worth $7,725,000 after acquiring an additional 6,312 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in Intercept Pharmaceuticals by 24.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,006 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 990 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Intercept Pharmaceuticals by 14.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 132 shares during the last quarter. 82.19% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($3.14) EPS.

Several brokerages recently weighed in on ICPT. Cantor Fitzgerald reaffirmed an “underweight” rating and issued a $69.00 target price (up from $60.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 8th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $221.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $275.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 20th. Finally, Royal Bank Of Canada began coverage on Intercept Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $244.00 target price on the stock. Three analysts have rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals has an average rating of “Hold” and an average target price of $174.93.

TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/25/stock-traders-buy-large-volume-of-intercept-pharmaceuticals-call-options-icpt.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.